Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: Biological synergy or an artefact of trial design?

European Journal of Cancer

Volumn 38, Issue 15, 2002, Pages 1957-1960

  Wright, T L ^a   Twelves, C J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; MELPHALAN; MITOMYCIN C; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE;

BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG CHOICE; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; HAND FOOT SYNDROME; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; DEOXYCYTIDINE; FEMALE; HUMANS; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 0036789758     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00167-3     Document Type: Editorial

References (18)

1. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capacitabine and docetaxel combination chemotherapy in anthracycline and pretreated patients with advanced breast cancer. J Clin Onco 2002, 20, 2812-2823.
2. Blum J.L., Jones S.E., Buzdar A.U.et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 17:1999;485-493.
3. Jones S., Winer E., Vogel C.et al. Randomized comparison of vinorelbine and melphelan in anthracycline-refractory advanced breast cancer. J. Clin. Oncol. 13:1995;2182-2567.
4. Nabholtz J.-M., Senn H.J., Bezwoda W.R.et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J. Clin. Oncol. 17:1999;1413-1424.
5. Slamon D.J., Leyland-Jones B., Shak S.et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792.
6. Henderson I.C., Allegra J.C., Woodcock T.et al. Randmized trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J. Clin. Oncol. 7:1998;560-571.
7. Joensuu H., Holli K., Heikkinen M.et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer. a prospective randomised trial J. Clin. Oncol. 16:1998;3720-3730.
8. Sjöstrom J., Blomqvist C., Mourisden H.et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure. a randomised phase III study with crossover on progression by the Scandinavian Breast Group Eur. J. Cancer. 35:1999;1194-1200.
9. Chan S., Friedrichs K., Noel D.et al. Prospective randomised trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 17:1999;2341-2354.
10. Paridaens R., Biganzoli L., Bruning P.et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer. a European Oganization for Research and Treatment of Cancer randomised study with cross-over J. Clin. Oncol. 18:2000;724-733.
11. Sledge, G.W. Jr, Neuberg, D., Ingle, J., et al. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin+paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an Intergroup trial. Proc. ASCO 1997, 16, 1a (abstr 2).
12. Miles D, Ayoub J-PM, O'Shaughnessy JA, et al. Survival benefit with Xeloda (capecitabine)/Taxotere (docetaxel) vs Taxotere: analysis of post study therapy. In Proc 24th Annual San Antonio Breast Cancer Symposium, 2001 (abstr 442).
13. Sawada N., Ishikawa T., Fukase Y.et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin. Cancer Res. 4:1998;1013-1019.
14. Kurosumi M., Tabei T., Suemasu K.et al. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol. Rep. 7:2000;945-948.
15. Fujimoto-Ouchi K., Tanaka Y., Tominaga T. Schedule dependency of antitumour activity in combination therapy with capecitabine/5-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin. Cancer Res. 7:2001;1079-1086.
16. Koroleva, I., Wojtukiewicz, M., Zaluski, J., et al. Preliminary results of a phase II randomised trial of taxotere (T) and doxorubicin (A) given in combination or sequentially as first line chemotherapy (CT) for metastatic breast cancer (MBC). Proc. ASCO 2001, 20, 30a (abstr 117)
17. Norris B., Pritchard K.I., James J.et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic breast cancer. National Cancer Institute of Canada Clinical Trials Group Study MA8 J. Clin. Oncol. 18:2000;2385-2394.
18. Biganzoli, L., Cufer, T., Bruning, P. et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicentre phase III trial. J. Clin. Oncol. 20, 3114-3121.